Edwards Lifesciences Corp Annual Report, Year Ended Dec 31, 2010

Edwards Lifesciences Corporation's 2010 10-K filing indicates a strong year of growth, with total net sales increasing by 9.5% to $1.45 billion. The company's Heart Valve Therapy segment was a primary driver, showing a 17.3% increase in net sales, largely due to the success of its transcatheter heart valves and new surgical valve offerings. The Critical Care and Cardiac Surgery Systems segments also saw modest growth. Geographically, international sales showed robust performance, growing by 14.9%, with Europe and Japan being key contributors. The company continued to invest heavily in research and development, allocating 14.1% of net sales to fuel innovation in its core product lines and emerging technologies. Financially, Edwards Lifesciences maintained a healthy gross profit margin of 71.8% and managed its selling, general, and administrative expenses effectively, with these expenses as a percentage of net sales decreasing slightly. The company also initiated a stock repurchase program, demonstrating a commitment to returning value to shareholders. Despite facing a dynamic and competitive market, the company's focus on technological advancement and addressing critical cardiovascular needs positions it for continued growth.